Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy



Status:Completed
Conditions:Allergy, Allergy, Neurology
Therapuetic Areas:Neurology, Otolaryngology
Healthy:No
Age Range:4 - 11
Updated:3/7/2019
Start Date:December 2015
End Date:August 18, 2017

Use our guide to learn which trials are right for you!

A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children

The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein
to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age
after a 12-month treatment by epicutaneous immunotherapy (EPIT).


Main Inclusion Criteria:

1. Male or female children aged 4 through 11 years;

2. Physician-diagnosis of peanut allergy or children with a well documented medical
history of IgE-mediated symptoms after ingestion of peanut and currently following a
strict peanut-free diet, but without a physician diagnosis;

3. Peanut-specific IgE level (ImmunoCAP system) >0.7 kU/L;

4. Positive peanut skin prick test (SPT) with a largest wheal diameter:

- ≥6 mm for children 4 through 5 years of age at Visit 1,

- ≥8 mm for children 6 years and above at Visit 1;

5. Positive DBPCFC at ≤300 mg peanut protein.

Main Exclusion Criteria:

1. History of severe anaphylaxis to peanut with any of the following symptoms:
hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or
incontinence);

2. Generalized dermatologic disease

3. Diagnosis of mast cell disorders, including mastocytosis or uricaria pigmentosa as
well as hereditary or idiopathic angioedema;

4. Diagnosis of asthma that fulfills any of the following criteria:

- Uncontrolled persistent asthma as defined by National Asthma Education and
Prevention Program Asthma guidelines 2007 or by Global Initiative for Asthma
guidelines 2015,

- Asthma treated with either a high daily high dose of inhaled corticosteroid or
with a combination therapy of a medium or high daily dose of inhaled
corticosteroid with a long acting inhaled β2 agonist or with a combination
therapy of a high daily dose of inhaled corticosteroid with a long acting inhaled
β2 agonist. Asthmatic subjects treated with a medium daily dose of inhaled
corticosteroids are eligible. Intermittent asthmatic subjects who require
intermittent use of inhaled corticosteroids for rescue are also eligible,

- Two or more systemic corticosteroid courses for asthma in the past year or 1 oral
corticosteroid course for asthma within 3 months prior to Visit 1, or during
screening period,

- Prior intubation/mechanical ventilation for asthma within 1 year prior to Visit
1, or during screening;

5. Receiving β-blocking agents, angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant
therapy;

6. Received anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or
any biologic immunomodulatory therapy within 1 year prior to Visit 1, during screening
period or during study participation;

7. Use of systemic long-acting corticosteroids within 12 weeks prior to Visit 1 and/or
use of systemic short-acting corticosteroids within 4 weeks prior to Visit 1 or during
screening;

8. Prior or concomitant history of any immunotherapy to any food;

9. Receiving or planning to receive any aeroallergen immunotherapy during their
participation in the study. Aeroallergen immunotherapy must be discontinued at the
time of Visit 1;

10. Any disorder in which epinephrine is contraindicated such as coronary artery disease,
uncontrolled hypertension, or serious ventricular arrhythmias.
We found this trial at
18
sites
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Principal Investigator: Jacqueline Pongracic, MD
Phone: 312-227-6474
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Wayne Shreffler, MD
Phone: 617-726-6147
?
mi
from
Boston, MA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Amal Assa'ad, MD
Phone: 513-636-6771
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Terri Brown-Whitehorn, MD
Phone: 215-590-2549
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Principal Investigator: Sharon Chinthrajah, MD
Stanford University School of Medicine Vast in both its physical scale and its impact on...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: David M. Fleischer, MD
Phone: 720-777-2575
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Robert Wood, MD
Phone: 418-659-7741
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Lynda Schneider, MD
Phone: 617-355-6180
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
Brisbane,
Principal Investigator: Peter Smith, MD
Phone: +61 7 3252 3711
?
mi
from
Brisbane,
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1935 Medical District Dr
Dallas, Texas 75235
(214) 456-7000
Principal Investigator: Drew Bird, MD
Phone: 214-456-3971
Children's Medical Center of Dallas Children's Medical Center is private, not-for-profit, and is the fifth-largest...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1400 Jackson St
Denver, Colorado 80206
(303) 388-4461
Principal Investigator: Donald Leung, MD
Phone: 303-398-1275
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Houston, Texas
Principal Investigator: Davis Carla, MD
Phone: 832-825-4668
?
mi
from
Houston, TX
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: Stacie M. Jones, MD
Phone: 501-364-1060
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Anna Nowak-Wegrzyn, MD
Phone: 212-241-5548
?
mi
from
New York, NY
Click here to add this to my saved trials
3414 Fifth Avenue
Pittsburgh, Pennsylvania 15213
Principal Investigator: Todd Green, MD
Phone: 412-692-8296
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
San Diego, California 92123
Principal Investigator: Stephanie Leonard, MD
Phone: 858-966-5961
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Seattle, Washington 98105
Principal Investigator: Stephen Tilles, MD
Phone: 206-525-5520
?
mi
from
Seattle, WA
Click here to add this to my saved trials